Get the Stockscreener App
2.02
0.49%
-0.010
After Hours:
2.02
Alx Oncology Holdings Inc stock is traded at $2.02, with a volume of 364.71K.
It is down -0.49% in the last 24 hours and down -0.98% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$2.03
Open:
$2.03
24h Volume:
364.71K
Relative Volume:
0.28
Market Cap:
$271.82M
Revenue:
-
Net Income/Loss:
$-101.70M
P/E Ratio:
-1.0653
EPS:
-1.8961
Net Cash Flow:
$-84.35M
1W Performance:
+5.21%
1M Performance:
-0.98%
6M Performance:
+34.67%
1Y Performance:
+283.88%
1-Day Range:
$2.01
$2.1063
1-Week Range:
$1.91
$2.1063
52-Week Range:
$0.51
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.02 | 273.16M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Mar-06-26 | Resumed | UBS | Buy |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
ALX Oncology Holdings Inc (ALXO) Cash Flow - TradingKey
2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC - MarketBeat
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010 - TradingKey
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
ALX Oncology Holdings Inc. Revenue Breakdown – NASDAQ:ALXO - TradingView
ALX Oncology Holdings Inc (ALXO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alx Oncology Holdings, Inc. (ALXO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alx Oncology Holdings, Inc. (ALXO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
ALX Oncology (ALXO) Status Update Summary - Quartr
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
ALXO Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ALX Oncology (ALXO) Jefferies London Healthcare Conference 2025 Summary - Quartr
ALX Oncology (ALXO) SVP sells 1,404 shares for RSU tax obligations - Stock Titan
ALXOAlx Oncology Holdings Inc Options - Finviz
ALX Oncology (ALXO) Edges Higher as Biotech Sector Shows Selective InterestLast Point Support - DonanımHaber
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology Appoints New Chairman Amid Leadership Changes - TipRanks
ALX Oncology grants 500,000-share option to new general counsel - Stock Titan
ALX Oncology's Corey Goodman resigns as Chairman and director - TradingView
Leadership shifts at ALX Oncology (NASDAQ: ALXO) as Garland becomes chair - Stock Titan
ALX Oncology names Scott Garland chairman, adds general counsel - Investing.com UK
ALX Oncology names Scott Garland chairman, adds general counsel By Investing.com - Investing.com India
ALXO Welcomes New Leadership with Board Changes - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - Investing News Network
ALX Oncology appoints Scott Garland as chairman and Michael Listgarten as general counsel to strengthen leadership - Traders Union
ALX Oncology replaces its chairman and adds a new general counsel - Stock Titan
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2500 Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Index - marketscreener.com
ALX Oncology Holdings Inc. (ALXO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 2000 Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Growth Benchmark - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell Microcap Index - marketscreener.com
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to Russell 3000E Index - marketscreener.com
ALXO Stock Edges Higher As Jefferies Conference Spotlights Oncology Pipeline - timothysykes.com
ALXO Rises As ALX Oncology Showcases Pipeline At Jefferies - StocksToTrade
Price to sales forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO - TradingView
Price to book forward of ALX Oncology Holdings Inc. – NASDAQ:ALXO - TradingView
ALX Oncology Secures New $50 Million Loan Facility - The Globe and Mail
Alx Oncology HoldingsEnters Loan And Security Agreement With HSBC Ventures On June 25, 2026SEC Filing - TradingView
ALX Oncology (NASDAQ: ALXO) adds up to $50M secured loan facility - Stock Titan
ALX Oncology Holdings, Inc. Actuals & Estimates (NASDAQ:ALXO) - TradingView
ALXO Forecast — Price Target — Prediction for 2027 - TradingView
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALX Oncology: Rebuilding From Critical Setbacks (NASDAQ:ALXO) - Seeking Alpha
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):